Overview
Classic hairy cell leukemia (HCL) is a rare, slow-growing type of blood cancer that affects a type of white blood cell called B lymphocytes. The name comes from the way the cancer cells look under a microscope — they have tiny hair-like projections on their surface. HCL is sometimes called hairy cell leukemia classic type to distinguish it from a rarer variant form. The disease causes the bone marrow to fill up with abnormal cells, which crowds out healthy blood cells and leads to low counts of red blood cells, white blood cells, and platelets. Because of these low blood counts, people with HCL often feel very tired, get infections easily, and may bleed or bruise more than usual. The spleen — an organ in the upper left belly — often becomes enlarged, which can cause discomfort or a feeling of fullness. Many people are diagnosed after a routine blood test shows abnormal results, even before they feel very sick. The good news is that HCL responds very well to treatment. Most people achieve long-lasting remission — meaning the cancer goes away or becomes undetectable — with a single course of chemotherapy. The most commonly used treatments are drugs called cladribine and pentostatin. While HCL is not usually considered curable in the traditional sense, many patients live for decades with excellent quality of life after treatment.
Also known as:
Key symptoms:
Extreme tiredness and fatigueFrequent or unusual infectionsEasy bruising or bleedingEnlarged spleen causing left-sided belly discomfort or fullnessFeeling full quickly when eatingUnexplained weight lossNight sweatsPale skinSwollen lymph nodes (less common)Weakness and low energy
Sporadic
Usually appears on its own, not inherited from a parent
Adult
Begins in adulthood (age 18 or older)
FDA & Trial Timeline
10 eventsNational Cancer Institute (NCI) — PHASE1, PHASE2
Betta Pharmaceuticals Co., Ltd. — PHASE1, PHASE2
David K Carroll — PHASE1, PHASE2
IRCCS Azienda Ospedaliero-Universitaria di Bologna — NA
National Cancer Institute (NCI) — PHASE2
IRCCS Azienda Ospedaliero-Universitaria di Bologna
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Memorial Sloan Kettering Cancer Center — PHASE2
Power Life Sciences Inc.
Stanford University — PHASE1
Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
Treatments
2 availableLUMOXITI
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nu…
LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).
Nipent
Single agent treatment for adult patients with alpha-interferon-refractory hairy cell leukemia.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Financial Resources
2 resourcesLeustatin Injection
R. W. Johnson Pharmaceutical Research Institute
Travel Grants
No travel grants are currently matched to Classic hairy cell leukemia.
Community
No community posts yet. Be the first to share your experience with Classic hairy cell leukemia.
Start the conversation →Latest news about Classic hairy cell leukemia
Disease timeline:
New recruiting trial: Hairy Cell Leukemia Patient Data Registry
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Decoding the Extracellular Vesicles-driven Communication in the Microenvironment of Hairy Cell Leukemia to Improve Patient Care Management
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Therapy Optimisation for the Treatment of Hairy Cell Leukemia
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
A new clinical trial is recruiting patients for Classic hairy cell leukemia
New recruiting trial: Assessment of Disease Burden in Hairy Cell Leukemia
A new clinical trial is recruiting patients for Classic hairy cell leukemia
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.Which treatment do you recommend for me, and why — cladribine or pentostatin?,How will we know if the treatment is working, and what does remission look like for my case?,What are the most common side effects of treatment, and how can I manage them?,How often will I need blood tests and check-ups after treatment?,What signs should I watch for that might mean the disease has come back?,Are there any clinical trials I should consider?,Are there any vaccines or medications I should avoid because of my weakened immune system?
Common questions about Classic hairy cell leukemia
What is Classic hairy cell leukemia?
Classic hairy cell leukemia (HCL) is a rare, slow-growing type of blood cancer that affects a type of white blood cell called B lymphocytes. The name comes from the way the cancer cells look under a microscope — they have tiny hair-like projections on their surface. HCL is sometimes called hairy cell leukemia classic type to distinguish it from a rarer variant form. The disease causes the bone marrow to fill up with abnormal cells, which crowds out healthy blood cells and leads to low counts of red blood cells, white blood cells, and platelets. Because of these low blood counts, people with H
How is Classic hairy cell leukemia inherited?
Classic hairy cell leukemia follows a sporadic inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Classic hairy cell leukemia typically begin?
Typical onset of Classic hairy cell leukemia is adult. Age of onset can vary across affected individuals.
Are there clinical trials for Classic hairy cell leukemia?
Yes — 19 recruiting clinical trials are currently listed for Classic hairy cell leukemia on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.
Which specialists treat Classic hairy cell leukemia?
25 specialists and care centers treating Classic hairy cell leukemia are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.
What treatment and support options exist for Classic hairy cell leukemia?
3 patient support programs are currently tracked on UniteRare for Classic hairy cell leukemia. See the treatments and support programs sections for copay assistance, eligibility, and contact details.